PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Glycerol Phenylbutyrate→

Glycerol Phenylbutyrate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
611168-24-2
Molecular formula
C33H38O6
Molecular weight
530.6 g/mol
Drug class
Nitrogen-scavenging prodrugglycerol ester of phenylbutyrate
Mechanism of action
Hydrolysed to phenylbutyrate, which is oxidised to phenylacetate. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted in urine and provides an alternative pathway for nitrogen waste elimination in urea-cycle disorders.
Indications / reported uses
  • Chronic management of patients with urea-cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino-acid supplementation alone; not for treatment of acute hyperammonaemia

Sources: US DailyMed — RAVICTI (glycerol phenylbutyrate) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Glycerol Phenylbutyrate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Glycerol Phenylbutyrate Permitted Daily Exposure (PDE) report (the Glycerol Phenylbutyrate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Glycerol Phenylbutyrate Occupational Exposure Limit (OEL) report (the Glycerol Phenylbutyrate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.